Allygen Biologics Raises Over 300 Million Yuan in Series A Round

Summarized by NextFin AI

Allygen Biologics completed a Series A financing round exceeding 300 million yuan, led by Sherpa Investment with participation from multiple institutional investors.
The funding will advance Allygen’s first STAR-BiADC candidate, ALG01, into Phase 1 clinical trials, while supporting additional pipeline development.
Allygen specializes in targeted conjugate therapeutics based on its STAR tumor-microenvironment activated release technology platform.

NextFin News — Allygen Biologics has completed a Series A financing round exceeding 300 million yuan.

The round was led by Sherpa Investment, with participation from the Beijing Pharmaceutical and Health Industry Investment Fund, Qiming Venture Partners, Zhuhai Science and Technology Industry Group, Huagai Capital, Taiyu Investment, W Capital and other investors. Fuan Capital acted as exclusive financial adviser.

Proceeds will support advancing the company’s first STAR-BiADC pipeline candidate ALG01 into Phase 1 clinical trials and the development of additional pipeline products. Allygen focuses on targeted conjugate therapeutics built on its STAR smart tumor-microenvironment activated release technology platform.

Explore more exclusive insights at nextfin.ai.

Insights

What is Allygen's STAR-BiADC technology?

How does smart tumor release work?

Why did Allygen raise Series A funding?

Who invested in Allygen's Series A?

How will 300 million yuan be used?

What is ALG01's Phase 1 trial plan?

When could ALG01 enter Phase 1?

What makes Allygen's platform different?

How does BiADC compare with ADC drugs?

What risks face ALG01's trials?

Can funding expand Allygen's pipeline?

How might targeted therapies evolve?

What market need does Allygen address?

Could investors shape Allygen's growth?

What are key hurdles for BiADC approval?

What is Allygen's next development step?

Search, ask or analyze anything...